Friday, July 10, 2026

Drug profile · INN

inotersen

inotersen (TEGSEDI) is a transthyretin antisense inhibitor.

EMA: approved Nervous system (N07) N07
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — inotersen
Class
Nervous system (N07)
Route
Patents
0
Programs
2
Data quality
0.83

Quick answer

inotersen (TEGSEDI) is a transthyretin antisense inhibitor.

Key facts

INN inotersen
Brand TEGSEDI
Mechanism Transthyretin ANTISENSE inhibitor
Therapeutic class Nervous system (N07)
ATC code N07

Mechanism of action

Transthyretin ANTISENSE inhibitor

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. Inotersen Phase 3 · IONIS PHARMACEUTICALS · FAP
  2. Inotersen Phase 3 · IONIS PHARMACEUTICALS · Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)

Frequently asked questions

What is inotersen?

inotersen (TEGSEDI) is a transthyretin antisense inhibitor.

What is the brand name for inotersen?

TEGSEDI is a marketed brand name for inotersen. Check FDA Drugs@FDA for the current US label holder and prescribing information.